Live Webinar·Catching CKD in primary care: Practical Steps to Reduce Cardiovascular Risk22 Oct 2026

Reference Point

COPD

A clinical reference for UK primary care

Last reviewed 22 May 2026 · Next review August 2026

In England, around 4.9% of adults aged 40 and over have a recorded diagnosis of chronic obstructive pulmonary disease (COPD), which is approximately 1.4 million people. A further 1.9% (around 500,000 people) have symptoms, an inhaler prescription, and a smoking history but no formal diagnosis. Prevalence rises sharply with age, reaching 10.2% in those aged 70 to 79.¹

Asthma + Lung UK estimates that around 750,000 people in England are misdiagnosed with asthma when they may have COPD, at an estimated cost of £132 million each year. The charity also highlights long waits for spirometry and 18-week treatment benchmarks frequently missed in respiratory medicine.²

NICE NG115 is the cornerstone clinical guideline for diagnosis and management. Diagnosis depends on suspecting COPD in people over 35 with a risk factor (typically smoking) and one or more respiratory symptoms, supported by post-bronchodilator spirometry showing an FEV1/FVC ratio below 0.7.³

Most COPD is managed in primary care. Severity is graded using post-bronchodilator FEV1 % predicted, but NG115 emphasises that single measures are insufficient and a range of prognostic factors should be considered alongside.³

Latest Analysis

Recent in copd

View all →

No articles tagged yet — check back soon.

Diagnosis

Diagnostic criteria

NG115 sets out a symptom-led approach supported by post-bronchodilator spirometry. The diagnosis is suspected on symptoms and signs, and supported by spirometry.³

NG115 recommendation 1.1.1. Suspect COPD in people over 35 who have a risk factor (generally smoking or a history of smoking) and present with one or more: exertional breathlessness, chronic cough, regular sputum production, frequent winter bronchitis, or wheeze.³

NG115 recommendation 1.1.5. Post-bronchodilator spirometry is required to confirm the diagnosis. Consider alternative diagnoses in older people with FEV1/FVC <0.7 but no typical symptoms (1.1.6).³

NG115 recommendation 1.1.3. Grade 1 = not troubled except on strenuous exercise; grade 5 = too breathless to leave the house, or breathless when dressing.³

NG115 recommendation 1.1.15. All patients should have a chest radiograph (to exclude other pathologies), full blood count (to identify anaemia or polycythaemia), and BMI calculated at the time of initial diagnostic evaluation.³

NG115 recommendation 1.1.18. Routine spirometric reversibility testing is not necessary as part of the diagnostic process or to plan initial therapy.³

NG115 recommendation 1.1.19 (Table 3) lists features that help differentiate. COPD: nearly always smoker or ex-smoker, symptoms rare under age 35, chronic productive cough common, persistent and progressive breathlessness, night-time waking with breathlessness uncommon, diurnal variability uncommon. Where both conditions are present or diagnostic uncertainty remains, a large (over 400 ml) bronchodilator response or 20% or greater peak flow variability points to asthma (1.1.21).³

Risk Stratification

Severity of airflow obstruction

Mild airflow obstruction. NG115 recommendation 1.1.27 specifies that COPD should only be diagnosed at this stage if the person also has one or more of the symptoms in 1.1.1.³

Moderate airflow obstruction. All stages require post-bronchodilator FEV1/FVC <0.7 to confirm COPD.³

Severe airflow obstruction. Consider assessment for long-term oxygen therapy in addition to optimised inhaled therapy (1.2.55).³

Very severe airflow obstruction (or FEV1 below 50% with respiratory failure). Twice-yearly primary care review per NG115 Table 6.³

Stopping smoking is the only intervention shown to slow lung function decline and reduce mortality in COPD. NG115 (1.2.3) recommends cessation support at every contact. NG209 recommendation 1.23.2 sets the expectation that all frontline staff are trained to offer very brief advice and refer to local stop-smoking support.^3,4

NG209 recommendation 1.12.2 lists the medicinally licensed options. Cytisinicline was added in February 2025. Combination short-acting and long-acting NRT is more effective than either alone (1.12.8). Behavioural support should be offered alongside any pharmacotherapy.⁴

NG115 recommendation 1.2.18 advises that inhaler choice should take into account symptom relief, patient preferences, and environmental impact. MDIs contain HFC propellant (≈19 kg CO2e per device); DPIs and SMIs contain no propellant (<1 kg CO2e). Patients should not switch without consultation — loss of disease control is a real risk. All used inhalers should be returned to pharmacy for safe disposal.^3,5

Ongoing Review

The annual care processes

The nine annual checks measured by the National Diabetes Audit.¹⁰

National Diabetes Audit

Track completion of all nine care processes for your practice

Smoking status

Ask at every contact and offer very brief advice plus referral to local stop-smoking support per NG209 (1.23.2)

Symptom control

Breathlessness, exercise tolerance, estimated exacerbation frequency

Pulmonary rehabilitation

Assess need; consider for those at MRC grade 3 or above

Inhaler technique

And effects of each drug treatment

Spirometry

FEV1 and FVC; calculate BMI; MRC dyspnoea score

Self-management plan

Review the individualised plan and exacerbation action plan (1.2.124–1.2.131)

Referral pathways

Diagnostic uncertainty

Per NG115 Table 5: refer when there is diagnostic uncertainty, when both COPD and asthma are present, or when the person reports a marked improvement in symptoms in response to inhaled therapy (1.1.23). Also refer if symptoms are disproportionate to the lung function deficit.³

Suspected severe COPD

Per NG115 Table 5: refer to confirm diagnosis and optimise therapy in suspected severe COPD, or where there is a rapid decline in FEV1, to encourage early intervention.³

Assessment for specific therapies

Per NG115 Table 5: refer for assessment for long-term oxygen therapy, long-term nebuliser therapy, oral corticosteroid therapy, pulmonary rehabilitation, lung volume reduction procedures, or lung transplantation.³

Onset under 40 or family history

Per NG115 Table 5: refer if symptoms begin under 40 years, or if there is a family history of alpha-1 antitrypsin deficiency, to identify the condition, consider therapy and screen family members. Bullous lung disease identified on imaging also warrants referral.³

Cor pulmonale or haemoptysis

Per NG115 Table 5: refer on the onset of cor pulmonale to confirm diagnosis and optimise therapy. Haemoptysis warrants referral to exclude carcinoma of the bronchus. Frequent infections warrant referral to exclude bronchiectasis.³

Find all NICE updates relevant to primary care

View NICE Guidelines

This disease hub is intended for UK Healthcare Professionals only. Content reports established clinical knowledge and current NICE guidance. It is not a substitute for clinical judgment or for the original guidelines. Last reviewed 22 May 2026.

References

All sources verified at last review. Where primary literature is cited, original peer-reviewed publications are linked.